Last updated 4 days ago
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
487 patients around the world
Available in Puerto Rico, Argentina, United States
Eli Lilly and Company
10Research sites
487Patients around the world
This study is for people with
Arterial hypertension
Obesity
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Refer to the GZPL master protocol study for screening eligibility.
- Refer to the GZPL master protocol study for screening eligibility.
Sites
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Centro de Investigaciones Clínicas Baigorria
Instituto de Investigaciones Clínicas Córdoba
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Médica - Rosario, Santa Fe
Instituto Médico Especializado (IME)
Centro Especialidades Médicas SRL (CEMEDIC)
Centro Médico Santa María de la Salud
INECO Neurociencias Oroño - Rosario
Dorado Medical Complex
Puerto Rico Medical Research Center
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Arterial hypertensionObesity
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06952530
